Good morning guys, most KLCI stocks are moving down in anticipation of Feds tightening interest rate further and which may cause global recession. The rot is beginning.
High oil prices and inflation are such a pain in the s now.
Fed must hike the interest rate, expected 75-100 basis points on Thursday Night (Malaysia Time), this means KLSE will only react to the terrible news and NYSE crashes on Friday.
So the final big boss KLSE market crash will only happen on Friday. leading up to the D Day, are just small crashes, just a preview of the armageddon. KLSE will go to 1300-1400.
KUALA LUMPUR: Merger and acquisition (M&A) of Genting Bhd's 20.3 per cent-owned research and development (R&D) associate TauRx Pharmaceuticals Ltd could allow for faster monetisation versus initial public offering (IPO), RHB Research said.
The firm said while Genting did not comment on its strategy with regards to its TauRx stake, any option of value realisation or monetisation was definitely a positive after having invested in the firm since November 2012.
"For TauRx to IPO, it would need to first commercialise its lead investigative oral drug, HMTM, in 2023 and undertake listing in 2024 or later.
"Conversely, we think M&A or in-licensing agreements may allow for earlier monetisation of Genting's stake, given that large pharmaceutical firms may have M&A interest in TauRx in order to possess the world's only effective Alzheimer's treatment.
"As a plus, M&A could allow TauRx to leverage on such firms' resources to expedite HMTM speed to market," it said in a note today.
RHB Research said the HMTM drug would need to undergo 12 months of open-label trials – it could seek regulatory approvals for this Alzheimer's drug before the trial's conclusion.
RHB Research said TauRx could contribute RM1.3 billion-RM4.3 billion to Genting's financial year 2024 (FY24)-FY26 earnings, assuming a 10 per cent net margin.
"It could also fetch an upside of RM3.47-RM13.88 a share share based on 10x price to earnings ratio (P/E) on our base and bull cases for FY24 earnings," it said.
RHB said this could translates to hypothetical target price of RM9.84-RM20.25 for Genting.
"Because HMTM's path to market and TauRx's value remains uncertain, we elect not to include the latter in Genting's valuation for now," it added.
RHB Research has maintained its "Buy" call on Genting, with an unhanged target price of RM6.37.
"TauRx's value accretion aside, we believe Genting's entities' recoveries makes it an attractive value 'Buy' with significant upside.
"At the current share price, investors are essentially getting its non-listed assets (potentially 20 per cent of TauRx) for free. Key risks include a prolonged pandemic, decrease in luck factor, and regulatory risks," it said.
No need to wait for end of 12 month open label for approval submission. The main focus regulators look at is on the first 12 month randomised and blinded phase 3 trial.
No need to wait for drug commercialisation before IPO. Many biotechs in NASDAQ are still not in late stage phase 3 trial, let alone commercialisation stage. Since 99.9% of AD drugs fail at phase 3, Taurx IPO will not be cheap. Investors can buy with certainty with successful phase 3 trial result.
A lot of wrong info articles flying around. Could be planted by whales. Maybank analyst attended ADI conference and reported the following data on HMTM revealed at the conference in London.
Primary Endpint: ADAS-COG = No Decline Primary Endpoint: ADCS-ADL = 67% slowdown in decline Secondary Endpoint: Brain atrophy = 50% slowdown in volume shrinkage
Read the trial announcement: "....participants receiving HMTM decline at a rate substantially less than is typical in Alzheimer’s based on published research. This was seen for both cognitive and functional endpoints across a broad range of severity from mild cognitive impairment (MCI) to moderate Alzheimer’s. Importantly, the safety profile is favourable and consistent with previous studies."
The report given by Maybank analyst who has attended ADI conference in London is consistent with what Taurx has announced. Not that I want to talk big abt Taurx.... No drugs' performance can surpass or even come anywhere near to HMTM's performance for the next 10 years. This drug is the Holy Grail for all AD patients, caregivers, doctors, govt, etc who have been waiting, praying and hoping for a miracle drug for the past few decades. HMTM will also go into the preventive AD market. Stop the disease before it starts to wreck havoc. Start the treatment early via PET scan for accumulation of toxic Tau tangles biomarkers even before physical AD symptoms appear. Huge existing AD market plus AD preventive market.
Still Taurx story… already mouldy story. I suspect some whales want another round of upside for Taurx play in Genting??? Very suspicious lah. Bilis will be taken for another Wild Ride??? Bilis got endless money to play according to Whales Playbook for another wild upside and then another Downside swing??? Your guess is as good as mine. Good luck baby.
True kah??? Whales Playbook for another wild Upside and then another wild Downside swing??? Where Bilis got money for another round of Wild Rides??? I don’t want to be taken for another round of roller coaster Wild ride???
I just be static. Non involve in another round of Wild Upside and Wild Downside. I will just sit tight to see my 25% holdings taken care by Whales Playbook. Nobody knows how is another round of Wild Rides. Thanks Bro and Sis
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
emsvsi
3,519 posts
Posted by emsvsi > 2022-06-12 21:44 | Report Abuse
YES KEN2004 HOW MUCH HAS TOPGLOVE LOST FROM THEIR SHARE BUYBACKS